CD109 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte line, with targeted disruption of CD109. This heterogeneous pool contains cells carrying diverse loss-of-function mutations in CD109, offering a versatile model for studying gene function without clonal bias. The product is intended for advanced biomedical research on T-cell signaling and leukemia.
The Jurkat cell line is an immortalized T-cell model established from the peripheral blood of a 14-year-old male with acute T-cell leukemia (T-ALL). Widely used to study T-cell receptor signaling, cytokine responses, and apoptosis, Jurkat cells retain key features of T lymphoblasts and serve as a robust system for investigating the molecular basis of T-ALL.
CD109 encodes a glycosylphosphatidylinositol-anchored glycoprotein that negatively regulates transforming growth factor-?? (TGF-??) signaling by binding TGFBR1 and TGFBR2, thereby inhibiting phosphorylation of SMAD2 and SMAD3. This attenuates SMAD-dependent transcription of targets such as SERPINE1 and CDKN1A. CD109 expression is regulated by TGFB1, interleukin-13, and T-cell receptor activation, and it modulates STAT3 activity, linking to JAK/STAT and PI3K/AKT pathways. Homodimerization further influences its receptor interaction, positioning CD109 as a key modulator at the nexus of several signaling networks.
In Jurkat T cells, TGF-?? signaling controls proliferation and survival. CD109 disruption may sensitize cells to TGF-??, potentially enhancing SMAD2/3 phosphorylation, altering expression of downstream targets, and shifting cell cycle or apoptotic responses. This model is particularly valuable for exploring T-ALL pathogenesis, where TGF-?? pathway dysregulation is common, and for dissecting how CD109 contributes to leukemogenesis.
Key applications include Western blotting for CD109 and phospho-SMAD2/3, SMAD-responsive luciferase reporter assays, annexin V flow cytometry for apoptosis monitoring, and MTT proliferation assays. RT-qPCR can quantify changes in TGF-?? target genes. This product supports studies of TGF-?? signaling in leukemia, screening for T-ALL regulators, and therapeutic target discovery. For more information, please reach out to Ascent Research.
